Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical…
7 analysts rate FMS Hold on consensus.
Consensus price target: $23.84 (+5.11% upside from $22.68)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $21.99B | +1.51% | $1.1B |
| 2024 | $21.66B | -0.61% | $602.6M |
| 2023 | $21.79B | +0.29% | $559M |
Stock data for FMS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics